PURPOSE: To investigate the effect of an anti-TNF-α agent (etanercept) on recovery processes in a partial spinal cord injury (SCI) model using clinical and electrophysiological tests. METHODS: Twenty-four New Zealand rabbits were divided into three groups: group 1 [SCI + 2 ml saline intramuscular (i.m.), n = 8], group 2 (SCI + 2.5 mg/kg etanercept, i.m., 2-4 h after SCI, n = 8) and group 3 (SCI + 2.5 mg/kg etanercept, i.m., 12-24 h after SCI, n = 8). Rabbits were evaluated before SCI, immediately after SCI, 1 week after, and 2 weeks after SCI, clinically by Tarlov scale and electrophysiologically by SEP. RESULTS: Tarlov scores of groups 2 and 3 were significantly better than group 1, 2 weeks after SCI. SEP recovery was significantly better in groups 2 and 3 than group 1, 2 weeks after SCI. CONCLUSIONS: These results show that blocking TNF-α mediated inflammation pathway by an anti-TNF-α agent enhances clinical and electrophysiological recovery processes in partial SCI model.
PURPOSE: To investigate the effect of an anti-TNF-α agent (etanercept) on recovery processes in a partial spinal cord injury (SCI) model using clinical and electrophysiological tests. METHODS: Twenty-four New Zealand rabbits were divided into three groups: group 1 [SCI + 2 ml saline intramuscular (i.m.), n = 8], group 2 (SCI + 2.5 mg/kg etanercept, i.m., 2-4 h after SCI, n = 8) and group 3 (SCI + 2.5 mg/kg etanercept, i.m., 12-24 h after SCI, n = 8). Rabbits were evaluated before SCI, immediately after SCI, 1 week after, and 2 weeks after SCI, clinically by Tarlov scale and electrophysiologically by SEP. RESULTS: Tarlov scores of groups 2 and 3 were significantly better than group 1, 2 weeks after SCI. SEP recovery was significantly better in groups 2 and 3 than group 1, 2 weeks after SCI. CONCLUSIONS: These results show that blocking TNF-α mediated inflammation pathway by an anti-TNF-α agent enhances clinical and electrophysiological recovery processes in partial SCI model.
Authors: Gracee Agrawal; David Sherman; Anil Maybhate; Michael Gorelik; Douglas A Kerr; Nitish V Thakor; Angelo H All Journal: J Clin Neurosci Date: 2010-06-09 Impact factor: 1.961
Authors: T Genovese; E Mazzon; C Crisafulli; E Esposito; R Di Paola; C Muià; P Di Bella; R Meli; P Bramanti; S Cuzzocrea Journal: Neuroscience Date: 2007-08-02 Impact factor: 3.590
Authors: Adam R Ferguson; Randolph N Christensen; John C Gensel; Brandon A Miller; Fang Sun; Eric C Beattie; Jacqueline C Bresnahan; Michael S Beattie Journal: J Neurosci Date: 2008-10-29 Impact factor: 6.167
Authors: Syed Faraz Kazim; Christian A Bowers; Chad D Cole; Samantha Varela; Zafar Karimov; Erick Martinez; Jonathan V Ogulnick; Meic H Schmidt Journal: Mol Neurobiol Date: 2021-08-03 Impact factor: 5.590
Authors: Ditte Gry Ellman; Minna Christiansen Lund; Maiken Nissen; Pernille Sveistrup Nielsen; Charlotte Sørensen; Emilie Boye Lester; Estrid Thougaard; Louise Helskov Jørgensen; Sergei A Nedospasov; Ditte Caroline Andersen; Jane Stubbe; Roberta Brambilla; Matilda Degn; Kate Lykke Lambertsen Journal: Cells Date: 2020-11-03 Impact factor: 6.600